Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Nanosonics Limited ( (AU:NAN) ).
Nanosonics Limited has announced a change in the director’s interest, specifically regarding Mr. Michael Kavanagh’s holdings. The change involves the exercise of 66,380 performance rights under the Nanosonics Omnibus Equity Plan, resulting in an increase in indirect ordinary shares held by Mr. Kavanagh. This adjustment reflects the company’s ongoing commitment to aligning leadership interests with shareholder value, potentially impacting stakeholder perceptions positively.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited operates in the medical technology industry, focusing on infection prevention solutions. The company is known for its innovative products, such as the trophon® EPR, which is a high-level disinfection system for ultrasound probes, and it aims to enhance safety and efficiency in healthcare environments.
YTD Price Performance: 38.54%
Average Trading Volume: 618,430
Technical Sentiment Signal: Hold
Current Market Cap: A$1.27B
For detailed information about NAN stock, go to TipRanks’ Stock Analysis page.